European Society for Medical Oncology

Type: Organization
Name: European Society for Medical Oncology
First reported Sep 22 2014 - Updated Sep 22 2014 - 2 reports

Endocyte Announces Late-Breaking Abstract Presentation at the European Society for Medical Oncology (ESMO) Conference

WEST LAFAYETTE, Ind., Sept. 22, 2014 (GLOBE NEWSWIRE) -- . (Nasdaq:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that an oral presentation will be presented ... [Published Wall Street Select - Sep 22 2014]
First reported Sep 22 2014 - Updated Sep 22 2014 - 1 reports

Reminder: Invitation to Roche's investor science conference call from ESMO 2014

Conference call on 29 September 2014Highlights to be discussed:We kindly invite investors and analysts to participate in a conference call to discuss new clinical data on the Roche oncology products and pipeline presented during the 2014 annual meeting ... [Published Noodls - Sep 22 2014]
First reported Sep 22 2014 - Updated Sep 22 2014 - 1 reports

Over 18,000 cancer specialists to attend ESMO 2014 Congress at FERIA DE MADRID

under theme “Precision Medicine in Cancer Care”The European Society for Medical Oncology, ESMO, will hold its annual congress at FERIA DE MADRID from 26 to 30 September. Oncologists and other professionals in the field will be able to discover the latest ... [Published IFEMA - Aula - Sep 22 2014]
First reported Sep 22 2014 - Updated Sep 22 2014 - 1 reports

Puma Biotechnology Updates on European Society for Medical Oncology Presentation [Professional Services Close - Up]

Puma Biotechnology recently reported that data from a Phase II clinical trial of its investigational drug PB272 (neratinib) for the treatment of patients with non-small cell lung cancer (NSCLC) that has a HER2 mutation will be presented as a late-breaking ... [Published Pharmacy Choice - Sep 22 2014]
First reported Sep 22 2014 - Updated Sep 22 2014 - 1 reports

Helsinn to Provide Independent Educational Grant Support for a Satellite Symposium on Delivering Chemotherapy with Confidence: New Strategies to Minimize Treatment-Induced Nausea and Vomiting at the 38th European Society for Medical Oncology (ESMO)

LUGANO, Switzerland, September 22, 2014 /PRNewswire/ --Helsinn Group, a company focused on building quality cancer care, today announces that it is supporting an independent educational satellite symposium on Delivering Chemotherapy With Confidence:. ... [Published PR Newswire: General Business - Sep 22 2014]
First reported Sep 22 2014 - Updated Sep 22 2014 - 1 reports

BRIEF-Exini to present BSI-results at conference in Madrit

Sept 22 (Reuters) - Exini Diagnostics AB* Says new BSI-results will be presented at cancerconference European Society for Medical Oncology (ESMO) 2014Congress in Madrid, SpainSource text for Eikon:Further company coverage:(gdynia.newsroom@thomsonreuters.com; ... [Published Reuters UK - Sep 22 2014]
First reported Sep 22 2014 - Updated Sep 22 2014 - 1 reports

EXINI: New BSI-results to be presented at cancer conference

New BSI-data have been generated using the software package, EXINI boneBSI, fora prostate cancer project. The results will be presented at the medical scienceconference “European Society for Medical Oncology (ESMO) 2014 Congress” inMadrid, Spain, September ... [Published GlobeNewswire - Sep 22 2014]
First reported Sep 18 2014 - Updated Sep 18 2014 - 1 reports

Eisai to present cancer drug data at ESMO 2014

:11 in Pharmaceutical Company Product News Eisai has announced that it will be presenting nine abstracts from its oncology portfolio at the 2014 European Society for Medical Oncology (ESMO) congress next week. The conference, which runs from September ... [Published Zenopa - Sep 18 2014]
First reported Sep 17 2014 - Updated Sep 18 2014 - 1 reports

Gilead Announces Data From Phase 2 Study of Simtuzumab for Previously Untreated Pancreatic Cancer

--Data to be Presented at European Society for Medical Oncology Congress in Madrid--. FOSTER CITY, Calif.---- Gilead Sciences, Inc. today announced results from a Phase 2 study evaluating simtuzumab, an investigational inhibitor of lysyl oxidase-like-2, ... [Published CNBC - Sep 17 2014]
First reported Sep 18 2014 - Updated Sep 18 2014 - 1 reports

Ignyta to Present RXDX-101 Phase I Data at 2014 ESMO Congress

Ignyta said that interim results from the first-in-human ALKA-372-001 Phase I clinical trial of RXDX-101, the company's proprietary oral tyrosine kinase inhibitor targeting solid tumor indications, was selected for presentation in a poster discussion ... [Published Individual.com - Sep 18 2014]
First reported Sep 17 2014 - Updated Sep 18 2014 - 1 reports

Novartis to present cancer drug data at ESMO 2014

:16 in Pharmaceutical Company Product News Novartis has announced that it will be attending the forthcoming 2014 European Society for Medical Oncology (ESMO) congress, where it will share data on its latest cancer drug developments. Taking place in Madrid ... [Published Zenopa - Sep 17 2014]
First reported Sep 17 2014 - Updated Sep 17 2014 - 1 reports

PharmaMar will be present at the 39th Congress of the European Society for Medical Oncology (ESMO 2014) with eight studies

PharmaMar will be present at the 39thMadrid, 17 September 2014 PharmaMar is a biopharmaceutical subsidiary of Grupo Zeltia; it is a world leader in discovering, developing and marketing marine-based drugs to treat cancer. Yondelis® is the first marine-based ... [Published Noodls - Sep 17 2014]

Quotes

...trally-acting kappa agonist molecules," said Stephen K Doberstein, Ph D , senior vice president and chief scientific officer of Nektar Therapeutics. "With this research, we are continuing to capitalize on the ability of our small molecule polymer medicinal chemistry platform to create new peripherally-acting molecules that could address different pain conditions."
"ESMO 2012 set the standard for what a congress should be: deep, comprehensive, and up-to-the-minute" he added. "ESMO 2014 will raise that standard to a new level."
Norbert Bischofberger, Gilead’s chief scientific officer, said: "Although simtuzumab did not provide clinical benefit in difficult-to-treat advanced pancreatic cancer patients in this study, we continue to explore simtuzumab in other areas of unmet medical need.”"
...Gary Hendler, president and chief executive officer for Eisai in Europe, said: "Eisai is committed to the provision of a range of options to help reduce the significant burden of cancer for patients, their families and healthcare systems." The company applied for EU and US regulatory approval of lenvatinib as a treatment for progressive radioiodine-refractory differentiated thyroid cancer...

More Content

All (77) | News (63) | Reports (0) | Blogs (10) | Audio/Video (0) | Fact Sheets (0) | Press Releases (4)
sort by: Date | Relevance
Simtuzumab Fails to Improve Outcomes in Pancrea... [Published CancerConnect.com - 10 hours ago]
KARYOPHARM THERAPEUTICS : Announces Three Clini... [Published 4 Traders - 20 hours ago]
Karyopharm Announces Three Clinical Data Presen... [Published Noodls - 20 hours ago]
Endocyte Announces Late-Breaking Abstract Prese... [Published GlobeNewswire: Advertising News - Sep 22 2014]
Endocyte Announces Late-Breaking Abstract Prese... [Published Wall Street Select - Sep 22 2014]
Endocyte Announces Late-Breaking Abstract Prese... [Published Fat Pitch Financials - Sep 22 2014]
Reminder: Invitation to Roche's investor scienc... [Published Noodls - Sep 22 2014]
Over 18,000 cancer specialists to attend ESMO 2... [Published IFEMA - Aula - Sep 22 2014]
ROCHE BEARER SHARE : Reminder: Invitation to Ro... [Published 4 Traders - Sep 22 2014]
Puma Biotechnology Updates on European Society ... [Published Pharmacy Choice - Sep 22 2014]
Helsinn to Provide Independent Educational Gran... [Published PR Newswire: General Business - Sep 22 2014]
BRIEF-Exini to present BSI-results at conferenc... [Published Reuters UK - Sep 22 2014]
EXINI: New BSI-results to be presented at cance... [Published GlobeNewswire - Sep 22 2014]
Nektar Presents Positive Preclinical Data on Ka... [Published BioMedReports - Sep 20 2014]
Merrimack Pharmaceuticals to Present Clinical a... [Published GlobeNewswire: Advertising News - Sep 19 2014]
Pancreatic Cancer Drug Simtuzumab Fails Mid-Sta... [Published PT Community - Sep 18 2014]
What's Hot at ESMO 2014 [Published American Journal of Public Health - Sep 18 2014]
Gilead's simtuzumab fails pancreatic cancer trial [Published PMLive - Sep 18 2014]
Eisai to present cancer drug data at ESMO 2014 [Published Zenopa - Sep 18 2014]
Tunnah’s musings: Taking the medical congress b... [Published pharmaphorum - Sep 18 2014]
Exelixis to present cobimetinib phase 3 coBRIM ... [Published PharmaBiz - Sep 18 2014]
Ignyta to Present RXDX-101 Phase I Data at 2014... [Published Individual.com - Sep 18 2014]
Flexion Therapeutics Announces Clinical Hold Of... [Published BioMedReports - Sep 18 2014]
ONCOSEC MEDICAL : to Present Data at ESMO 2014 ... [Published 4 Traders - Sep 17 2014]
Gilead’s Pancreatic Cancer Drug Disappoints [Published Bidness Etc - Sep 17 2014]
OncoMed to Present New and Emerging Data From D... [Published GlobeNewswire: Acquisitions News - Sep 17 2014]
Gilead's simtuzumab fails pancreatic cancer trial [Published Pharma Times - Sep 17 2014]
Novartis to present cancer drug data at ESMO 2014 [Published Zenopa - Sep 17 2014]
Gilead Announces Data From Phase 2 Study of Sim... [Published CNBC - Sep 17 2014]
Exelixis Announces Cobimetinib Phase 3 coBRIM R... [Published Investor's Business Daily - Sep 17 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Helsinn to Provide Independent Educational Gran... [Published PR Newswire: General Business - Sep 22 2014]
LUGANO, Switzerland, September 22, 2014 /PRNewswire/ --Helsinn Group, a company focused on building quality cancer care, today announces that it is supporting an independent educational satellite symposium on Delivering Chemotherapy With Confidence:. ...
Exelixis Announces Cobimetinib Phase 3 coBRIM R... [Published Business Wire Health News - Sep 17 2014]
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ:EXEL) today announced that cobimetinib, an Exelixis-discovered compound, will be the subject of a clinical data presentation at the European Society for Medical Oncology (ESMO) 2014 ...
Ignyta Announces RXDX-101 Phase I Data Presenta... [Published EON Science - Sep 15 2014]
SAN DIEGO--(EON: Enhanced Online News)--Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, today announced that interim results from the first-in-human ALKA-372-001 Phase I clinical trial of RXDX-101, the company’s proprietary ...
Ignyta Announces RXDX-101 Phase I Data Presenta... [Published Business Wire Science: Science News - Sep 15 2014]
SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, today announced that interim results from the first-in-human ALKA-372-001 Phase I clinical trial of RXDX-101, the company’s proprietary oral ...
Ignyta Announces RXDX-101 Phase I Data Presenta... [Published Business Wire Health News - Sep 15 2014]
SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, today announced that interim results from the first-in-human ALKA-372-001 Phase I clinical trial of RXDX-101, the company’s proprietary oral ...
1 2

Press Releases

sort by: Date | Relevance
Endocyte Announces Late-Breaking Abstract Prese... [Published GlobeNewswire: Advertising News - Sep 22 2014]
Merrimack Pharmaceuticals to Present Clinical a... [Published GlobeNewswire: Advertising News - Sep 19 2014]
OncoMed to Present New and Emerging Data From D... [Published GlobeNewswire: Acquisitions News - Sep 17 2014]
Karyopharm Announces Three Clinical Data Presen... [Published GlobeNewswire: Acquisitions News - Sep 09 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.